ALGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aligos Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $-25.07 Mil. Aligos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-86.26 Mil. Aligos Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was 344.83%.
The historical rank and industry rank for Aligos Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Aligos Therapeutics was 1053.18%. The lowest was -1640.44%. And the median was 137.15%.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Aligos Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
The historical data trend for Aligos Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Earnings Yield (Joel Greenblatt) % | Get a 7-Day Free Trial | - | -12.52 | -38.76 | 135.14 | 117.65 |
Aligos Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Earnings Yield (Joel Greenblatt) % | Get a 7-Day Free Trial | 158.73 | 232.56 | 322.58 | 117.65 | 344.83 |
For the Biotechnology subindustry, Aligos Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Aligos Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings Yield (Joel Greenblatt) | = | EBIT | / | Enterprise Value |
= | -88.127 | / | -74.7016584 | |
= | 117.97 % |
Aligos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.26 Mil.
Aligos Therapeutics (NAS:ALGS) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.
Thank you for viewing the detailed overview of Aligos Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Roche Finance Ltd | 10 percent owner | C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8 |
Roche Holding Ltd | 10 percent owner | ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070 |
Carole Nuechterlein | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Matthew W. Mcclure | officer: Chief Medical Officer | C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Bridget A Martell | director | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
James Paul Scopa | director | 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Thomas Woiwode | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Vivo Capital Surplus Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Julian A. Symons | officer: See Remarks | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Leonid Beigelman | director, officer: President | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Lucinda Y. Quan | officer: See Remarks | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Lawrence Blatt | director, officer: Chief Executive Officer |
From GuruFocus
By Marketwired • 10-03-2023
By GuruFocus Research • 11-02-2023
By GlobeNewswire • 06-21-2023
By sperokesalga sperokesalga • 02-08-2023
By Value_Insider Value_Insider • 12-08-2022
By sperokesalga sperokesalga • 05-24-2023
By Marketwired • 11-03-2023
By sperokesalga sperokesalga • 04-27-2023
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.